59651-087 : Sevelamer Hydrochloride 400 mg Oral Tablet, Film Coated
NDC: | 59651-087 |
Labeler: | Aurobindo Pharma Limited |
Product Type: | Human Prescription Drug |
Drug Name: | Sevelamer Hydrochloride |
Dosage Form: | Oral Tablet, Film Coated |
Application #: | ANDA212599 |
Rev. Date: |
NDC Package Codes:
- 59651-087-36: 360 TABLET, FILM COATED IN 1 BOTTLE (59651‑087‑36)
Active Ingredients:
- Sevelamer Hydrochloride
Dosage Strength:
- 400 mg
Pharmaceutical Classes:
- Phosphate Binder [EPC]
- Phosphate Chelating Activity [MoA]
Related Products:
Based on records with the same trade name.- 59651-088 Sevelamer Hydrochloride 800 mg Oral Tablet, Film Coated by Aurobindo Pharma Limited
- 0955-1048 Sevelamer Hydrochloride 800 mg Oral Tablet, Film Coated by Winthrop U.S.
- 33342-241 Sevelamer Hydrochloride 400 mg Oral Tablet, Film Coated by Macleods Pharmaceuticals Limited
- 33342-242 Sevelamer Hydrochloride 800 mg Oral Tablet, Film Coated by Macleods Pharmaceuticals Limited
- 60687-449 Sevelamer Hydrochloride 800 mg Oral Tablet, Film Coated by American Health Packaging
- 68462-446 Sevelamer Hydrochloride 400 mg Oral Tablet, Film Coated by Glenmark Pharmaceuticals Inc., USA
- 68462-447 Sevelamer Hydrochloride 800 mg Oral Tablet, Film Coated by Glenmark Pharmaceuticals Inc., USA
- 70748-172 Sevelamer Hydrochloride 400 mg Oral Tablet by Lupin Pharmaceuticals, Inc.
- 70748-173 Sevelamer Hydrochloride 800 mg Oral Tablet by Lupin Pharmaceuticals, Inc.
- 72603-148 Sevelamer Hydrochloride 800 mg Oral Tablet, Film Coated by Northstar Rxllc
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 59651-086Next: 59651-088 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.